Listen to Story New drug Zaynich has shown 97% effectiveness against multi-drug resistant infections It is currently nearing completion of a multi-national Phase III study Zaynich is a combination of ...

Mumbai: Wockhardt has announced that Zaynich (Zidebactam/Cefepime, WCK 5222) demonstrated over 97 percent clinical efficacy in treating seriously ill patients with infections caused by ...

and E. coli. Treatment durations ranged from 7 to 21 days, and the study protocol was approved by the Drugs Controller General of India (DCGI). Zaynich, a combination of Zidebactam & Cefepime, is ...

"In a ground-breaking clinical study, Zaynich (Zidebactam/Cefepime, WCK 5222) demonstrated over 97 per cent clinical efficacy in treating seriously ill patients with infections caused by ...

Wockhardt Limited announced that its innovative antibiotic, Zaynich (Zidebactam/Cefepime), demonstrated over 97% clinical efficacy in treating serious infections ...

In a retrospective, observational analysis, the authors found that empirical V- piperacillin-tazobactam was associated with a higher mortality than V-cefepime. V-piperacillin-tazobactam’s ...

Purpose: The pharmacology, spectrum of activity, pharmacokinetics, clinical efficacy, adverse events, dosage and administration, drug interactions, and place in therapy of tigecycline are reviewed ...

Background: Cefepime is a fourth-generation cephalosporin antibiotic used to treat a variety of infections. The US Food and Drug Administration approved its use in certain types of infections among ...

Pursuant to Regulation 30 of SEBI Listing Regulations, please find enclosed Press Release - "Wockhardt''s Zaynich (Zidebactam/Cefepime, WCK 5222) achieves highest-ever efficacy meeting superiority in ...